Axsome Therapeutics, Inc.
NASDAQ:AXSMBiotechnology
+$0.25 today
- Market cap
- $7.05B
- Beta
- 0.60
- P/E (TTM)
- -68.6
- EPS (TTM)
- -$3.68
Volume 0.74M
Average 0.72M
AXSM Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Axsome Therapeutics, Inc.NASDAQ: AXSM
Accounts Receivables · Q2 FY2026 · quarter ended Jun 2026
Accounts receivables dips below year-ago levels
Q2 FY2026 accounts receivables of $26.4M (cash outflow) fell 29.5% year over year, behind the +0.2% change in trailing-twelve-month accounts receivables. Sequentially, it fell 0.8% from the prior quarter. Over 3 fiscal years it compounded at +29.8% a year.
Context
- Accounts receivables amounted to 12.9% of revenue in FY2025, up 0.7 pp from a year earlier.
- Accounts receivables grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -29.5% toward the trailing-twelve-month pace of +0.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (82.46M) USD
- Year-over-year change
- -74.8%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (82.46M) | -74.8% |
| FY2024 | 2024-12-31 | (47.18M) | +17.4% |
| FY2023 | 2023-12-31 | (57.12M) | -51.5% |
| FY2022 | 2022-12-31 | (37.7M) | — |
| FY2021 | 2021-12-31 | 0 | — |
Accounts Receivables vs competitors
How AXSM compares with its peers on the latest reported figures
- AXSM's LTM Jun 2026 accounts receivables of $78.63M is the 2nd largest of the 11 companies compared; the peer median is $82.44K.
- Its year-over-year change of +0.2% is the 2nd highest of 6, against a peer median of -20.0%.
- Accounts receivables amounts to 10.1% of revenue for AXSM, versus a peer median of 5.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $197.5M | -20.0% | +9.1% | 5.3% | |
| LTM Jun 2026 | $78.63M | +0.2% | +29.8% | 10.1% | |
| LTM Jun 2026 | $47.41M | -506.5% | +10.9% | 5.7% | |
| LTM Sep 2026 | $37.81M | -4.5% | +5.6% | 0.8% | |
| LTM Jun 2026 | $3.93M | — | — | 109.0% | |
| LTM Dec 2025 | $1.71M | +72.7% | -34.9% | — | |
| LTM Sep 2026 | $106.87K | -192.1% | -61.0% | — | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $58K | — | — | 0.3% |
| LTM Sep 2026 | $0 | — | — | — | |
DFTXDefinium Therapeutics, Inc. | LTM Sep 2026 | $0 | — | — | — |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $0 | — | — | — |
| Peer median (excluding AXSM) | $82.44K | -20.0% | +5.6% | 5.3% | |
Competitors are the stored peer set for AXSM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (130.4M) | (187.13M) | (239.24M) | (287.22M) | (183.17M) |
| Depreciation & Amortization | 76K | 4.4M | 6.83M | 7.96M | 9.06M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 20.8M | 37.73M | 62.62M | 85.22M | 93.75M |
| Change in Working Capital | 324K | 23.67M | (28.39M) | 33.9M | (22.52M) |
| Accounts Receivables | 0 | (37.7M) | (57.12M) | (47.18M) | (82.46M) |
| Inventory | (6K) | (5.28M) | (8.16M) | (2.44M) | (15.67M) |
| Accounts Payables | (355K) | 25.46M | 2.07M | 31.32M | (6.46M) |
| Other Working Capital | 685K | 41.19M | 34.81M | 52.2M | 82.07M |
| Other Non-Cash Items | 974K | 4.83M | 53.1M | 31.73M | 9.48M |
| Operating Cash Flow | (108.23M) | (116.51M) | (145.08M) | (128.41M) | (93.41M) |
| Capital Expenditures | (308K) | (702K) | (582K) | (270K) | (480K) |
| Acquisitions (Net) | 0 | (53M) | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (308K) | (53.7M) | (582K) | (270K) | (480K) |
| Debt Repayment | 0 | 45M | 85M | (990K) | (7.75M) |
| Common Stock Issued | 7.44M | 243.76M | 258.75M | 40.78M | 126.27M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.69M | (4.18M) | (12.74M) | 18.05M | (17.05M) |
| Financing Cash Flow | 11.13M | 284.58M | 331.01M | 57.84M | 101.47M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (97.4M) | 114.37M | 185.35M | (70.84M) | 7.58M |
| Free Cash Flow | (108.53M) | (117.21M) | (145.66M) | (128.68M) | (93.89M) |
Axsome Therapeutics, Inc.
NASDAQ:AXSM
Intrinsic Alpha fair value
Locked
Current Price
$134.00
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.